Physician profile
Wei Liu
NPI 1902251804
$6,392.01
in general payments reported to CMS, 2019-2025
30 companies · $2,169 in 2025
The $2,169 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $215 · 2021: $281 · 2022: $452 · 2023: $1,345 · 2024: $1,793 · 2025: $2,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,307.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $759.09 | 2022-2025 | Ozempic, Rybelsus |
| Amgen INC. | $716.23 | 2024-2025 | Evenity, Repatha, Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $609.73 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $492.14 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $489.30 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $442.77 | 2023-2025 | |
| Abbvie INC. | $393.98 | 2022-2025 | |
| Exact Sciences Corporation | $323.45 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $302.29 | 2023-2025 | Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $218.22 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $207.45 | 2020-2023 | Belsomra, Steglatro |
| Astellas Pharma US INC | $167.57 | 2023-2024 | Veozah, Myrbetriq |
| Nestle Healthcare Nutrition INC. | $162.76 | 2021 | |
| Cequr Corporation | $141.60 | 2023 | Cequr Simplicity |
| Celgene Corporation | $125.00 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $124.90 | 2025 | Dupixent |
| Kerecis Limited | $114.56 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Axonics, INC. | $95.97 | 2024 | Axonics |
| Vbi Vaccine (Delaware) INC. | $90.96 | 2022-2023 | Prehevbrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.09 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $64.81 | 2025 | Ibsrela |
| Organon LLC | $54.98 | 2025 | Nexplanon |
| Amarin Pharma, INC. | $39.83 | 2022-2023 | |
| Phadia US INC. | $39.64 | 2023-2024 | Immunocap |
| Insmed, INC. | $28.48 | 2023 | Arikayce |
| Agios Pharmaceuticals, INC. | $26.48 | 2025 | Pyrukynd |
| Agile Therapeutics, INC. | $22.71 | 2024 | Twirla |
| Hologic Sales and Service, LLC | $17.14 | 2024 | Aptima |
| Melinta Therapeutics, LLC | $15.28 | 2024 | Kimyrsa, Vabomere, Rezzayo |
| Horizon Therapeutics Plc | $14.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.